SMC2: Key Regulator of DNA Replication and Cell Adhesion (G10592)

Target Name: SMC2

NCBI ID: G10592

SMC2

SMC2: Key Regulator of DNA Replication and Cell Adhesion

SMC2 (Spermidine-2-carboxylic acid) is a protein that is expressed in various cell types of the human body. It is a key player in the regulation of DNA replication and repair, and is involved in the development and maintenance of chromatin structure. SMC2 has also been shown to play a role in the regulation of cell adhesion, and has been implicated in a number of diseases, including cancer.

SMC2 is a member of the Spermidine family of proteins, which are characterized by the presence of a disulfide bond between two cysteine ??????residues. These proteins are involved in a variety of cellular processes, including DNA replication, protein synthesis, and signaling.

SMC2 is a key regulator of DNA replication and repair. During DNA replication, SMC2 helps to ensure that the accurate replication of the genetic information in the cell. It does this by playing a role in the formation of a double helix, which is the standard structure of DNA replication.

SMC2 is also involved in the regulation of cell adhesion. Adhesion is the process by which cells stick together and form tissues. SMC2 helps to regulate the stickiness of cells to each other, allowing them to move and change position in a coordinated manner. This is important for the development and maintenance of tissues and organs, and is also implicated in the regulation of many diseases, including cancer.

SMC2 has also been shown to play a role in the regulation of many other cellular processes, including cell signaling, cell cycle progression, and the regulation of gene expression. It is also involved in the regulation of inflammation, and has been shown to play a role in the development of cancer.

SMC2 is a potential drug target for a number of diseases. For example, it has been shown to be involved in the development of many types of cancer, including breast, ovarian, and prostate cancer. It is also involved in the regulation of cell adhesion , which could make it a useful target for diseases that are characterized by the breakdown of cell barriers.

In addition to its potential as a drug target, SMC2 is also a valuable biomarker for a number of diseases. For example, it has been shown to be a useful biomarker for breast cancer, and has been used to diagnose and monitor the effectiveness of many types of cancer treatments.

Overall, SMC2 is a protein that is involved in a number of important cellular processes, and has been implicated in a number of diseases. Further research is needed to fully understand its role in these processes, and to develop effective treatments for diseases that are characterized by the dysfunction of SMC2.

Protein Name: Structural Maintenance Of Chromosomes 2

Functions: Central component of the condensin complex, a complex required for conversion of interphase chromatin into mitotic-like condense chromosomes. The condensin complex probably introduces positive supercoils into relaxed DNA in the presence of type I topoisomerases and converts nicked DNA into positive knotted forms in the presence of type II topoisomerases

The "SMC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets